Search results
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 5 hours agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Is It Too Late to Buy Pfizer Stock?
Motley Fool via Yahoo Finance· 1 day agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 2 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer Inc. (NYSE:PFE) Shares Sold by Public Employees Retirement System of Ohio
ETF DAILY NEWS· 1 day agoPublic Employees Retirement System of Ohio reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 2 days agoPfizer disclosed on May 7 that a child participating in another...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 3 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 2 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 2 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 3 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
